Preclinical Safety Evaluation of a Prophylactic Viral Vector Vaccine against the Human Respiratory Syncytial Virus (RSV)
Poster Authors:
Xiaonan Liang, Dandan Feng, Panpan Ma, Jufeng Wang
Pharmaron (Beijing) TSP Services Limited, Beijing, China
In this poster, we present a vaccine safety study of a prophylactic vaccine. We investigate the safety of a viral vector vaccine based on a virus known for eliciting robust immune responses without causing illness in recipients. The vaccine recombinantly expresses the F-protein, a surface protein of RSV, to trigger a targeted immune response, thereby enhancing the body’s ability to recognize and combat RSV.
In this study, 120 rats were administered various doses of the prophylactic vaccine for safety assessment purposes. The following readouts were conducted:
- Overall safety and tolerability in the animals
- Induction of humoral immune response against the vector virus and the target protein
- Induction of cellular immune response through analysis of IFN-gamma-secreting lymphocytes
- Immunotoxicity evaluation
- Histopathological assessment
Capabilities
The outcome of this vaccine safety study may facilitate future vaccine design efforts and expedite the progression of viral vector vaccines into clinical trials.
Download the poster to learn more about prophylactic vaccine safety.